2002
DOI: 10.1038/sj.onc.1206085
|View full text |Cite
|
Sign up to set email alerts
|

Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
37
0

Year Published

2005
2005
2015
2015

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(39 citation statements)
references
References 64 publications
2
37
0
Order By: Relevance
“…For example, both B lineage and T cell ALLs showed an up-regulation of RNA-binding genes and of genes involved in transcription. An altered activity of RNA-binding genes has previously been associated with neoplastic transformation (29). In addition, all three subtypes showed down-regulation of genes involved in cell adhesion, indicating a common defect among all leukemic cases, regardless of lineage.…”
Section: Discussionmentioning
confidence: 84%
“…For example, both B lineage and T cell ALLs showed an up-regulation of RNA-binding genes and of genes involved in transcription. An altered activity of RNA-binding genes has previously been associated with neoplastic transformation (29). In addition, all three subtypes showed down-regulation of genes involved in cell adhesion, indicating a common defect among all leukemic cases, regardless of lineage.…”
Section: Discussionmentioning
confidence: 84%
“…27 Some reports discuss likely post-transcriptional mechanisms involving shuttling RNA-binding proteins in leukemogenesis. 28 A number of other genes that encode proteins with RNA-binding domains are rearranged in human cancer. 29 As is the case in TS-2, each of these RNA-binding proteins is fused to a transcription factor with DNA-binding properties, but there is no clear understanding whether, and if so how, their RNA-binding properties contribute to transformation.…”
Section: Resultsmentioning
confidence: 99%
“…Studying IKAROS isoform expression in BCR-ABL1 þ pre-B lymphoblastic leukemia, expression of dominantnegative IK6 was detected in six of seven primary cases (cases XIII-XIX in Klein et al, 2004) and two of three cell lines (in BV173 and SUP-B15, but not in Nalm1 cells). As shown by us and others, BCR-ABL1 can induce aberrant splicing of various genes (Perrotti and Calabretta, 2002), including SLP65 (Jumaa et al, 2003;Klein et al, 2004), PYK2 (Salesse et al, 2004) and BTK . Consistent with BCR-ABL1-induced derangement of IKAROS pre-mRNA splicing, patient-derived leukemia cells express dominant-negative IKAROS (IK6) before, but not during extended therapy with the BCR-ABL1 kinase inhibitor STI571 (Figure 2d).…”
Section: Bcr-abl1 Induces Defective Expression Of Ikarosmentioning
confidence: 99%